SEC Filing Summary: PerkinElmer, Inc. (10-Q)
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for PerkinElmer, Inc. for the period ended April 3, 2005. The company operates in three reporting segments: Life and Analytical Sciences, Optoelectronics, and Fluid Sciences. The filing covers the first quarter of fiscal year 2005 and includes unaudited financial statements and management discussion.
Key Financial Metrics
| Metric | Q1 2005 | Q1 2004 |
|---|---|---|
| Sales | $416.3 million | $392.6 million |
| Operating Income | $35.6 million | $29.9 million |
| Net Income | $19.8 million | $13.3 million |
| Diluted EPS | $0.15 | $0.10 |
| Gross Margin | 40.7% | 38.9% |
| Cash from Operations | $13.4 million | $25.0 million |
| Total Debt | $374.4 million | N/A |
| Cash and Equivalents | $184.2 million | $197.5 million (Jan 2, 2005) |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 6% year-over-year, driven by a 6% increase in Life and Analytical Sciences and a 13% increase in Optoelectronics. Fluid Sciences sales declined 5%.
- Margin Expansion: Gross margin improved by 180 basis points to 40.7%, attributed to better leverage of fixed costs and productivity improvements.
- Acquisition Impact: The company acquired Elcos AG in February 2005 for approximately $15.4 million in cash plus earn-outs. This contributed $2.5 million to Optoelectronics sales.
- Expense Increases: R&D expenses rose 17% to $23.7 million, and SG&A expenses rose 7% to $102.6 million, reflecting investments in growth platforms and headcount.
- Cash Flow: Operating cash flow decreased significantly to $13.4 million from $25.0 million in the prior year, primarily due to a $11.0 million net increase in working capital (inventory and receivables).
Outlook, Risks, and Contingencies
- Capital Expenditures: Management anticipates total capital expenditures of $20.0 to $30.0 million for fiscal 2005.
- Debt Management: The company holds $300 million in 8 7/8% senior notes due 2013 and a senior credit facility with $70 million outstanding on the term loan. Interest rate swaps were utilized to convert $200 million of fixed-rate debt to variable rates.
- Legal Proceedings: The company is involved in significant litigation, including patent infringement suits with Enzo Biochem and Amersham Biosciences, as well as a class action lawsuit regarding alleged misleading statements about future operating results. No material loss is currently estimable.
- Environmental Liabilities: An accrual of $3.8 million exists for environmental remediation, with potential exposure not expected to be materially different from recorded amounts.
- Accounting Changes: The company expects to adopt SFAS No. 123R in Q1 2006, which will increase stock-based compensation expense.
Investor Verification Checklist
- Verify the integration progress and revenue contribution of the Elcos AG acquisition.
- Monitor working capital trends, specifically the increase in inventory and accounts receivable impacting cash flow.
- Review the status of pending litigation (Enzo, Amersham, and class action) for potential financial impact.
- Assess the impact of foreign exchange rates on future earnings, given over 50% of sales are international.
- Confirm compliance with debt covenants, particularly interest coverage and leverage ratios.